CO5640121A2 - Un metodo de tratamiento de un trastorno de la ansiedad - Google Patents
Un metodo de tratamiento de un trastorno de la ansiedadInfo
- Publication number
- CO5640121A2 CO5640121A2 CO06001545A CO06001545A CO5640121A2 CO 5640121 A2 CO5640121 A2 CO 5640121A2 CO 06001545 A CO06001545 A CO 06001545A CO 06001545 A CO06001545 A CO 06001545A CO 5640121 A2 CO5640121 A2 CO 5640121A2
- Authority
- CO
- Colombia
- Prior art keywords
- disorder
- treatment
- anxiety disorder
- adenosine
- receptor antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Abstract
1.- Un método de tratamiento de un trastorno de ansiedad seleccionado entre el grupo consistente en trastorno del pánico, agorafobia, trastorno obsesivo-compulsivo, fobia social, trastorno del estrés post-traumático y fobia específica, caracterizado porque comprende administrar una cantidad efectiva de al menos un antagonista de los receptores de adenosina A2A a un paciente que lo necesite.2.- El método de tratamiento de un trastorno de ansiedad según la reivindicación 1, caracterizado porque el antagonista de los receptores de adenosina A2A es un derivado de xantina o una sal farmacéuticamente aceptable del mismo.3.- El método de tratamiento de un trastorno de ansiedad según la reivindicación 1, caracterizado porque el antagonista de los receptores de adenosina A2A es un compuesto representado por la fórmula (I): [donde R1, R2 y R3 representan independientemente hidrógeno, alquilo inferior, alquenilo inferior o alquinilo inferior;R4 representa cicloalquilo, -(CH2)n-R5 (donde R5 representa arilo substituido o sin substituir o un grupo heterocíclico substituido o sin substituir y n es un número entero de 0 a 4) o la fórmula (l-i) (donde Y1 y Y2 representan independientemente hidrógeno,halógeno o alquilo inferior y Z representa arilo substituido o sin substituir o un grupo heterocíclico substituido o sin substituir), y X1 y X2 representan independientemente O o S], o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50904603P | 2003-06-10 | 2003-06-10 | |
| US53279303P | 2003-12-24 | 2003-12-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5640121A2 true CO5640121A2 (es) | 2006-05-31 |
Family
ID=33514319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO06001545A CO5640121A2 (es) | 2003-06-10 | 2006-01-10 | Un metodo de tratamiento de un trastorno de la ansiedad |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8202869B2 (es) |
| EP (1) | EP1631294B1 (es) |
| JP (1) | JP4778894B2 (es) |
| KR (1) | KR20060037252A (es) |
| CN (1) | CN1787821A (es) |
| AT (1) | ATE481101T1 (es) |
| AU (1) | AU2004244906A1 (es) |
| BR (1) | BRPI0411120A (es) |
| CA (1) | CA2528710C (es) |
| CO (1) | CO5640121A2 (es) |
| DE (1) | DE602004029160D1 (es) |
| EA (1) | EA200501924A1 (es) |
| MX (1) | MXPA05013148A (es) |
| NO (1) | NO20055907L (es) |
| WO (1) | WO2004108137A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE043353T2 (hu) * | 2002-01-28 | 2019-08-28 | Kyowa Hakko Kogyo Kk | A2A receptor antagonisták mozgás zavarok kezelésében történõ alkalmazásra |
| US10042980B2 (en) | 2005-11-17 | 2018-08-07 | Gearbox Llc | Providing assistance related to health |
| US10296720B2 (en) | 2005-11-30 | 2019-05-21 | Gearbox Llc | Computational systems and methods related to nutraceuticals |
| US20070124176A1 (en) * | 2005-11-30 | 2007-05-31 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational and/or control systems and methods related to nutraceutical agent selection and dosing |
| US20070136092A1 (en) * | 2005-11-30 | 2007-06-14 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging |
| EP2089389A2 (en) | 2006-11-01 | 2009-08-19 | Bristol-Myers Squibb Company | Heterocyclic compounds as modulators of glucocorticoid receptor, ap-1, and/or nf-kappa-b activity |
| JP2010534674A (ja) * | 2007-07-23 | 2010-11-11 | シノシア・セラピューティクス | 心的外傷後ストレス障害の治療用４−ヒドロキシ−４−メチル−ピペリジン−１−カルボン酸（４−メトキシ−７−モルホリン−４−イル−ベンゾチアゾール−２−イル）−アミド |
| UA113383C2 (xx) | 2009-09-02 | 2017-01-25 | Терапевтичний агент для лікування тривожних розладів | |
| UA110097C2 (uk) | 2009-09-02 | 2015-11-25 | Терапевтичний агент для лікування розладів настрою | |
| US8609162B2 (en) | 2012-10-04 | 2013-12-17 | Invivo Beverages Llc | Integrated neuromodulation system for mood enhancement of a living human subject |
| CN105770563A (zh) * | 2016-04-22 | 2016-07-20 | 孙建 | 一种治疗焦虑症的中药制剂及其制备方法 |
| IL303087B1 (en) | 2018-02-27 | 2024-08-01 | Incyte Corp | Midazopyrimidines and triazolopyrimidines as A2A /A2B inhibitors |
| US11168089B2 (en) | 2018-05-18 | 2021-11-09 | Incyte Corporation | Fused pyrimidine derivatives as A2A / A2B inhibitors |
| CN113166153A (zh) | 2018-07-05 | 2021-07-23 | 因赛特公司 | 作为a2a/a2b抑制剂的稠合吡嗪衍生物 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| WO2022167778A1 (en) | 2021-02-02 | 2022-08-11 | Haiku Therapeutics Ltd | Ebselen as adenosine receptor modulator |
| KR102594242B1 (ko) | 2023-01-10 | 2023-10-27 | 주식회사 웨이센 | 디지털 표현형 특징을 이용한 사회 불안장애 분석방법 및 장치 |
| KR102567684B1 (ko) | 2023-01-10 | 2023-08-18 | 주식회사 웨이센 | 디지털 표현형 특징을 이용한 사회 불안장애 분석방법 및 장치 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988002370A1 (en) * | 1986-09-30 | 1988-04-07 | Ciba-Geigy Ag | 2-substituted-e-fused-[1,2,4]triazolo[1,5-c]pyrimidines pharmaceutical compositions and uses thereof |
| US5047534A (en) * | 1990-03-26 | 1991-09-10 | Merrell Dow Pharmaceuticals Inc. | Selective adenosine receptor agents |
| US5484920A (en) | 1992-04-08 | 1996-01-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for Parkinson's disease |
| CA2116967C (en) | 1992-07-08 | 2003-08-19 | Fumio Suzuki | Antidepressants |
| WO1999012546A1 (fr) | 1997-09-05 | 1999-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Remede contre la degenerescence neurale |
| EP1116722B1 (en) * | 1998-09-22 | 2005-01-12 | Kyowa Hakko Kogyo Co., Ltd. | [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES |
| WO2000069464A1 (fr) * | 1999-05-12 | 2000-11-23 | Fujisawa Pharmaceutical Co., Ltd. | Nouvelle utilisation |
| KR100520907B1 (ko) * | 2000-05-26 | 2005-10-11 | 쉐링 코포레이션 | 아데노신 Ａ2ａ수용체 길항제 |
| MXPA04002389A (es) * | 2001-09-13 | 2004-05-31 | Schering Corp | Combinacion de un antagonista del receptor de adenosian a2a y un antidepresivo o ansiolitico. |
| CN100421663C (zh) * | 2001-10-15 | 2008-10-01 | 先灵公司 | 咪唑并（4,3－E）,1,2,4－三唑并（1,5－C）嘧啶类化合物作为腺苷A2a受体拮抗剂 |
| AU2002340405A1 (en) * | 2001-11-20 | 2003-06-10 | Bristol-Myers Squibb Pharma Company | 3,7-dihydro-purine-2,6-dione derivatives as crf receptor ligands |
| US20060128694A1 (en) * | 2002-12-19 | 2006-06-15 | Michael Grzelak | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
-
2004
- 2004-06-10 AU AU2004244906A patent/AU2004244906A1/en not_active Abandoned
- 2004-06-10 EP EP04746014A patent/EP1631294B1/en not_active Expired - Lifetime
- 2004-06-10 EA EA200501924A patent/EA200501924A1/ru unknown
- 2004-06-10 US US10/553,250 patent/US8202869B2/en not_active Expired - Fee Related
- 2004-06-10 BR BRPI0411120-6A patent/BRPI0411120A/pt not_active IP Right Cessation
- 2004-06-10 AT AT04746014T patent/ATE481101T1/de not_active IP Right Cessation
- 2004-06-10 WO PCT/JP2004/008486 patent/WO2004108137A1/en active Application Filing
- 2004-06-10 MX MXPA05013148A patent/MXPA05013148A/es unknown
- 2004-06-10 KR KR1020057021878A patent/KR20060037252A/ko not_active Application Discontinuation
- 2004-06-10 CA CA2528710A patent/CA2528710C/en not_active Expired - Fee Related
- 2004-06-10 JP JP2006516839A patent/JP4778894B2/ja not_active Expired - Fee Related
- 2004-06-10 DE DE602004029160T patent/DE602004029160D1/de not_active Expired - Lifetime
- 2004-06-10 CN CNA2004800128457A patent/CN1787821A/zh active Pending
-
2005
- 2005-12-13 NO NO20055907A patent/NO20055907L/no not_active Application Discontinuation
-
2006
- 2006-01-10 CO CO06001545A patent/CO5640121A2/es not_active Application Discontinuation
-
2012
- 2012-04-16 US US13/447,798 patent/US8592420B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP4778894B2 (ja) | 2011-09-21 |
| US20120232089A1 (en) | 2012-09-13 |
| MXPA05013148A (es) | 2006-03-17 |
| US20060281770A1 (en) | 2006-12-14 |
| US8592420B2 (en) | 2013-11-26 |
| ATE481101T1 (de) | 2010-10-15 |
| EA200501924A1 (ru) | 2006-06-30 |
| DE602004029160D1 (es) | 2010-10-28 |
| CA2528710A1 (en) | 2004-12-16 |
| KR20060037252A (ko) | 2006-05-03 |
| AU2004244906A1 (en) | 2004-12-16 |
| JP2006527264A (ja) | 2006-11-30 |
| CN1787821A (zh) | 2006-06-14 |
| BRPI0411120A (pt) | 2006-07-18 |
| WO2004108137A1 (en) | 2004-12-16 |
| NO20055907L (no) | 2005-12-13 |
| EP1631294B1 (en) | 2010-09-15 |
| CA2528710C (en) | 2012-04-17 |
| EP1631294A1 (en) | 2006-03-08 |
| US8202869B2 (en) | 2012-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5640121A2 (es) | Un metodo de tratamiento de un trastorno de la ansiedad | |
| CY1120384T1 (el) | Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων | |
| DE60305052D1 (de) | Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden | |
| ATE490984T1 (de) | Methode zur produktion und evaluierung der zytotoxizität von kir2dl nk-rezeptor antikörpern | |
| DE60314500D1 (de) | Diaminopyrimidine und deren verwendung als angiogenesehemmer | |
| EA200700708A1 (ru) | Мемантин для лечения расстройств поведения детского возраста | |
| IS8432A (is) | Mótefni sem bindast viðtaka hvítfrumuboða-4 | |
| TW200606177A (en) | Glycoprotein VI antibodies and methods thereof | |
| DK1660528T3 (da) | Mutein af tåre-lipocalin | |
| NO20061239L (no) | Fremgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelser | |
| ATE464303T1 (de) | Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen | |
| NO20052242L (no) | Noytraliserende antistoffer mot GDF-8 og deres anvendelse. | |
| ATE541859T1 (de) | Humane anti-interferon-gamma-antikörper und verfahren zu ihrer verwendung | |
| WO2005116088A3 (en) | Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells | |
| BR0308928A (pt) | Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular | |
| ATE451376T1 (de) | Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen | |
| WO2004084835A3 (en) | Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor | |
| DE602004024037D1 (de) | Substituierte heterozyklen | |
| DE602006017574D1 (de) | Als protein-kinase-inhibitoren nutzbare benzimidazole | |
| MX2010005047A (es) | Inhibidores de aldh-2 en el tratamiento de enfermedades psiquiatricas. | |
| DK1480627T3 (da) | Fremgangsmåder til mindskelse af angiogenese | |
| NO20074780L (no) | Heterocyklylamidsubstituerte imidazoler | |
| NO20082203L (no) | Fremgangsmater for a behandle sentralnervesystemforstyrrelser med en lavdosekombinasjon av escitalopram og bupropion | |
| TW200507840A (en) | Method of treating multiple myeloma | |
| EA200601220A1 (ru) | Анти-trkc антитела-агонисты и способы их применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |